

WestminsterResearch

<http://www.westminster.ac.uk/westminsterresearch>

**Griseofulvin solvate solid dispersions with synergistic effect
against fungal biofilms**

Al-Obaidi, H., Kowalczyk, R.M., Kalgudi, R. and Zariwala, M.

NOTICE: this is the authors' version of a work that was accepted for publication in Colloids and Surfaces B: Biointerfaces. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Colloids and Surfaces B: Biointerfaces, 184, 2019.

The final definitive version in Colloids and Surfaces B: Biointerfaces is available online at:

<https://dx.doi.org/10.1016/j.colsurfb.2019.110540>

© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <https://creativecommons.org/licenses/by-nc-nd/4.0/>

The WestminsterResearch online digital archive at the University of Westminster aims to make the research output of the University available to a wider audience. Copyright and Moral Rights remain with the authors and/or copyright owners.

26 **Abstract**

27 Fungal biofilms are invariably recalcitrant to antifungal drugs and thus can
28 cause recurrent serious infections. The aim of this work was to prepare highly
29 effective form of the antifungal drug griseofulvin using the chloroform solvate
30 embedded into different polymeric matrices. Based on their solid solubility,
31 solvated (chloroform) and non-solvated (methanol and acetone) solid
32 dispersions were prepared using different materials: silica, microcrystalline
33 cellulose, polyvinylpyrrolidone and hydroxypropyl methylcellulose acetate
34 succinate (HPMCAS) by which HPMCAS dispersions showed the highest
35 solubility of about 200 µg/mL compared with ~30 µg/mL for pure griseofulvin.
36 The anti fungal potential of griseofulvin was assessed against the
37 dermatophytes *T. rubrum*. Metabolic and protease activity of *T. rubrum* NCPF
38 935 with and without the presence of GF:HPMCAS chloroform solvates
39 showed significant reduction compared to the untreated control after 24 h
40 period. Confocal laser scanning microscopy showed thin hyphae compared to
41 Control and GF:HPMCAS (non solvated). Dynamic vapour sorption data
42 showed that HPMCAS formed most stable solvate structure preventing
43 recrystallization and solvate expulsion, which could explain the disruptive
44 effect of the biofilms. This could be explained by the formed hydrogen bonds
45 as revealed by the solid and liquid state NMR data, which was further
46 confirmed via thermal and FTIR analyses.

47

48

49

50

51 **1. Introduction**

52

53 Biofilms are surface-associated microbial communities that exist within a self-
54 secreted matrix consisting primarily of polysaccharides, proteins and nucleic
55 acids forming the biofilm extracellular matrix (ECM) [1, 2]. Biofilm structures
56 formed by fungi may present favourable conditions for survival within an
57 infected host [3]. Dermatophytes such as *T. rubrum*, keratinolytic, saprophytic
58 fungi, are known to form biofilm and commonly implicated as a common
59 cause for athlete's foot and fungal infection of the nails [4]. Griseofulvin is one
60 of the most commonly used antimicrobials to treat dermatophytosis caused by
61 *T. rubrum* [5] nevertheless, there have been reports of increased incidence of
62 resistance to griseofulvin, which makes treatment with griseofulvin less
63 effective [6, 7]. This could be attributed to the biofilm formation and longer
64 duration needed to complete the treatment.

65

66 The low aqueous solubility of griseofulvin makes its formulation particularly
67 challenging for oral drug delivery , which results in larger doses needed to
68 reach a therapeutic level. Hence, the challenge in improving the antifungal
69 activity of griseofulvin is two folds; first to improve its aqueous solubility and
70 secondly to overcome resistance due to biofilm formation. Crystal
71 modifications of drug forming metastable drug polymorphs, hydrates, and co-
72 crystals have been among various approaches to improve aqueous solubility
73 of drugs [8-10].

74

75 Solvates (also known as pseudopolymorphs) comprise of solvent-drug
76 crystals, which have completely different structural configuration to the parent
77 drug crystals [11]. Recently, it has been shown that ethanol solvates can
78 significantly improve the dissolution of pioglitazone with potential
79 enhancement of *in vivo* levels in beagle dogs [12]. It is generally agreed that
80 solvates can form through either adsorption to the crystal cell surface or
81 though occupying voids within imperfect crystals [13]. It was shown recently
82 that dextran shell nanoparticles eradicated biofilms of various multidrug-
83 resistant Gram-positive bacteria [14]. This effect was attributed to improved
84 solubility of the bacteria-nanoparticles complex due to the presence of the
85 dextran shell [14]. Based on chloroform solvate, the aim of this work was to
86 prepare a highly synergistic solvate form of griseofulvin able to diffuse across
87 the biofilms and enhance their solubility. The solvate form is stabilised within
88 a polymeric matrix, which will also help to enhance the aqueous solubility of
89 the embedded drug.

90

91 Griseofulvin (GF) was embedded within different matrices, namely silica,
92 microcrystalline cellulose (MCC), polyvinylpyrrolidone (PVP) and
93 hydroxypropyl methylcellulose acetate succinate (HPMCAS). GF and the
94 polymer dispersions were prepared using acetone, methanol and chloroform
95 as solvents. They were selected because of their distinct properties in terms
96 of hydrogen bonds formation, boiling point and polarity. Chloroform and
97 methanol are Lewis acids with unique properties of chloroform to form Cl...Cl
98 interactions while acetone is Lewis base with distinct proton accepting
99 capability. By using different matrices, it was possible to evaluate the impact

100 of drug excipient interactions on crystallization behaviour. Silica is amorphous
101 that lacks hydrogen bonding ability, PVP is a Lewis base amorphous polymer
102 able to accept hydrogen bonds, MCC is partially crystalline able to accept and
103 donate hydrogen bonds while HPMCAS is amorphous polymer and hydrogen
104 bond acceptor and donor.

105

106

107 **2. Experimental Section**

108 **2.1. Materials**

109

110 Griseofulvin 97%, silicon dioxide nanopowder 99.5%, microcrystalline
111 cellulose (MCC) and polyvinylpyrrolidone (PVP) K30 were purchased from
112 Sigma-Aldrich (Dorset, UK). Hydroxypropyl methylcellulose acetate succinate
113 (HPMCAS) was obtained from Shin-Etsu Chemical Co. Ltd (Tokyo, Japan).
114 Acetone, chloroform and methanol were purchased from Fisher Scientific
115 (Loughborough, UK). Ethanol, potassium dihydrogen phosphate, KH_2PO_4
116 and sodium hydroxide, NaOH pellets were obtained from VWR International
117 (Leicestershire, UK).

118

119

120 **2.2. Dynamic vapor sorption**

121 Solid dispersions of GF (10 mg) were weighed at 25 °C using a Dynamic
122 Vapor Sorption analyzer (SMS, UK). Two sources of nitrogen gas were used
123 where one of them is a dry gas while the second is 100% moist. By mixing
124 both of them, the desirable relative humidity was obtained. The variation in

125 weight was recorded using a two-arm balance where the reference pan was
126 empty and the sample pan was filled with the sample. Nitrogen gas was
127 passed over the sample to remove the residual solvent content (using 0%
128 relative humidity). Once this was achieved, nitrogen gas is passed with the
129 desired relative humidity (RH).

130

131 **2.3. Differential Scanning Calorimetry (DSC)**

132 Thermal analysis was performed on a 2920 TA Instruments (Hertfordshire,
133 UK) differential scanning calorimeter calibrated with indium using a purge of
134 nitrogen gas at 20mL/min. A pinhole was created on an aluminium lid (TA
135 instruments) to remove residual solvent. 8-10mg of sample was loaded into
136 an aluminium pan and hermetically sealed. The samples were scanned from
137 10°C to 250°C using a heating rate of 10°C/min. The melting enthalpy, onset
138 and peak melting temperature were recorded and their values represent an
139 average value of triplicates.

140

141

142 **2.4. Fourier transform infrared spectroscopy (FTIR)**

143 FTIR was performed on the prepared dispersions to examine potential
144 hydrogen bonding between GF and the polymers. The infrared spectra of
145 samples were obtained using Perkin Elmer Spectrum One FTIR spectrometer,
146 equipped with a diamond attenuated total reflectance (ATR) accessory
147 (Shelton, Connecticut, USA). A total of 64 scans were collected for each
148 sample with a resolution of 4cm⁻¹ from a frequency range of 4000cm⁻¹ to
149 550cm⁻¹.

150

151 **2.5. Saturation solubility measurements**

152 From each solid mixture quantities equivalent to 5mg-10mg equivalent of
153 griseofulvin was weighed. 1mL of phosphate buffer was added into the
154 microtube which was then loaded on a Stuart SB2 rotary mixer (Staffordshire,
155 UK) and mixed for 1, 3, 5 and 72 h. This was followed by centrifugation for 10
156 min at 13000 RPM on a Heraeus Biofuge Pico 24-place microliter centrifuge
157 (Thermo Scientific, Hertfordshire, UK). The supernatant was separated and
158 the UV absorbances of the supernatants were measured using a Thermo
159 Scientific Spectronic spectrophotometer (Thermo Scientific, Waltham, USA)
160 using a wavelength of 295nm. Absorbance values were converted into
161 solubility values using standard calibration curve of griseofulvin. Solubility
162 studies were conducted in triplicates and the average and standard deviations
163 were calculated.

164

165

166 **2.6. Temperature controlled X-ray powder diffraction**

167 The polymorphic nature of the formed samples was studied using x-ray
168 powder diffraction (XRPD). All samples were scanned using a Bruker D8
169 advance X-ray diffractometer (Bruker AXS GmbH, Germany) which is a Cu-
170 source, theta–theta diffractometer equipped with a Lynx eye position
171 sensitive detector. It was operated at 40 kV generator voltage and 40 mA
172 generator current. The samples were analysed using DFFRAC plus XRD
173 commander software (Bruker AXS GmbH, Germany) with a 2θ range of 5-45°,
174 a step size of 0.02° and time per step of 1.33s. Glass Capillary x-ray

175 diffraction data were collected on Bruker D8 Advance Material lightly ground
176 and packed in 0.7 mm capillary, which was then heated with a co-axially,
177 mounted cryostream. Compact controller set to ramp to temperature, then
178 held for 5 minutes to allow the capillary to warm up, before collecting data.
179 This was followed by a ramp to next temperature, hold, collect cycle within a
180 temperature range of 30-200 °C.

181

182 **2.7. Solid and liquid state NMR**

183 Solid and liquid state NMR studies were used to investigate structural
184 changes of GF within the solvated and non-solvated polymeric matrices. ¹H
185 and ¹³C NMR spectra of GF chloroform-*d* solution were recorded on Bruker
186 Avance III spectrometer (Bruker, Germany) operating at Larmor frequency of
187 500 MHz (11.75T) and 125.78 MHz, respectively. The 32 transients were
188 recorded and average into each ¹H spectrum. The proton decoupled ¹³C
189 experiment required 1024 transients, and was recorded with 8 sec relaxation
190 delay. The selected 2D experiments (e.g. COSY, TOCSY, HSQC and HMBC)
191 were also recorded to confirm the assignments of the GF peaks to the
192 molecular structure (data not shown). All spectra were referenced using TSP
193 signal at 0 ppm.

194

195 The ¹³C solid-state cross-polarization magic angle spinning (CPMAS) NMR
196 spectra were recorded on Bruker Avance III spectrometer (Bruker, Germany)
197 operating at Larmor frequency of 125.78 MHz (11.75T). The standard bore
198 MAS probe was used in conjunction with 4 mm diameter zirconia rotors, which
199 were spun at 10 kHz rate. The CP contact time was 2.0 ms, and the 90°

200 pulse width was 3.7 us at a power level of 32 W. Between 256 (for GF and
201 HPMCAS) and 1024 (all other samples) signal transients were accumulated
202 with 6 sec relaxation delays at ambient temperature. All spectra were
203 referenced to external adamantane signal as a secondary reference
204 (frequency peak at 38.0 ppm).

205

206 **2.8. Preparation of drug-polymer solvates and non-solvated** 207 **counterparts**

208 Fixed weight ratios (w/w ratios) of GF and polymer, i.e. silica, microcrystalline
209 cellulose (MCC), polyvinylpyrrolidone (PVP) and hydroxypropyl
210 methylcellulose acetate succinate (HPMCAS) were weighed and fully
211 dissolved in solvent of choice (acetone, methanol or chloroform) which was
212 then removed using rotary evaporator (Buchi Rotavapor RE-111, Oldham,
213 UK) with a set water bath temperature of 40 °C. The solid remained in the
214 flask was transferred to another container and placed under vacuum to be
215 dried for 24h to eliminate any residual solvent. The resultant solid was co-
216 ground for 10min and sieved via 80 µm sieve.

217

218 **2.9. Preparation of fungal inoculum**

219 In order to study differences among prepared formulations, *in vitro* studies
220 were carried out using fungal biofilms. *T. rubrum* NCPF 935 (PHE, UK)
221 inoculum was prepared from initial growth on potato dextrose agar (PDA)
222 (Sigma-Aldrich, UK) as mentioned by Brillhante *et al.*, 2017 with a few
223 modifications [15]. Briefly, 39 g/L of the solids were fully dissolved in 1 L of
224 distilled water and then sterilised at 121 °C for 15 min. The molten agar was

225 poured into petri plates once it had cooled down to ~ 55 °C and allowed to
226 set. A small piece of *T. rubrum* NCFP 935 was excised from the stock and
227 placed in the centre of the PDA plates and allowed to grow for a period of 7-
228 10 days at 28 °C for optimal sporulation. The conidia and hyphal fragments
229 were harvested by covering the cultures with 5 mL of sterile 0.9% saline
230 solution and by passing a sterile swab over the surface of the cultures. The
231 0.9% saline solution containing the conidia and hyphal fragments was then
232 collected and allowed to settle for 5 min at 28 °C to sediment the hyphae and
233 separate the conidia. The conidium suspension was then gently aspirated and
234 transferred to fresh sterile tubes and serially diluted to obtain a suspension
235 containing ~ 5 x 10⁶ cfu/ mL. This was based on cell count performed using a
236 haemocytometer. The conidia suspension was then diluted with 0.9% saline
237 solution to obtain a concentration of ~ 1 x10⁶ cfu/ mL for biofilm formation and
238 subsequent experiments.

239

240 **2.10 Working stock of griseofulvin formulations for biofilm assay**

241

242 GF:HPMCAS formulations were initially dissolved in DMSO (dimethyl
243 sulfoxide) (Sigma-Aldrich, UK) according to the CLSI broth microdilution
244 protocol (Wayne, 2008) to a concentration of 800 µg/ mL. The formulations
245 were then further diluted in RPMI 1640 medium, buffered to pH 7 with MOPS
246 to obtain the desired concentrations for biofilm formation assay.

247

248 **2.11. *T. rubrum* NCPF 935 biofilm formation assay**

249 Biofilm formation by *T. rubrum* NCPF 935 was performed based on the
250 method as mentioned by dos Santos and Dias-Souza, 2017; Costa-Orlandi *et*

251 *al.*, 2014 with a few modifications [16]. Briefly, 250 μ L of the pre-adjusted (\sim 1
252 $\times 10^6$ cfu/ mL) conidia suspension was added to 96-well plates as required.
253 The plates were then incubated at 37 $^{\circ}$ C for 3 h for adhesion of the conidia to
254 the surface of the wells under static conditions. Subsequently, the growth
255 suspension was replaced with pre-sterilised 250 μ L of RPMI 1640 (pH 7)
256 medium containing GF:HPMCAS (chloroform solvate) and non solvated
257 (prepared from acetone). **The concentration of the formulations used in this**
258 **study were equivalent to the MIC of griseofulvin against *T. rubrum* (8 μ g/ mL),**
259 **which were prepared following CLSI (the clinical and laboratory standards**
260 **institute guidelines) M38-A2 for fungal work.** Biofilm of *T. rubrum* NCPF 935
261 was grown with and without the addition of the formulation and grown for a
262 period of 96 h at 37 $^{\circ}$ C prior to carrying out subsequent assays.

263

264

265 **2.12. Quantification of *T. rubrum* NCPF biofilm by safranin staining**

266 Biofilm formation by *T. rubrum* NCPF 935 was performed based on previous
267 method with a few modifications [16, 17]. Briefly, 250 μ L of the pre-adjusted
268 (\sim 1 $\times 10^6$ cfu/ mL) conidia suspension was added to 96-well plates as
269 required. The plates were then incubated at 37 $^{\circ}$ C for 3 h for adhesion of the
270 conidia to the surface of the wells under static conditions. Subsequently, the
271 growth suspension was replaced with pre-sterilised 250 μ L of RPMI 1640 (pH
272 7) medium containing GF:HPMCAS (chloroform solvate) and non solvated
273 (prepared from acetone). **The concentration of the formulations used in this**
274 **study were equivalent to the known MIC₉₀ of griseofulvin against *T. rubrum* (8**
275 **μ g/ mL) as demonstrated previously [18] were prepared following clinical and**

276 laboratory standards institute (CLSI) guidelines M38-A2 for fungal work.

277 Biofilm of *T. rubrum* NCPF 935 was grown with and without the addition of the

278 formulation and grown for a period of 96 h at 37 °C prior to carrying out

279 subsequent assays.

280 The concentration of GF:HPMCAS (solvated and non-solvated) used in this

281 study are provided in Table 1 (supplementary material). The total

282 concentration (w/v) of GF:HPMCAS used for the *in vitro* studies was based on

283 MIC₉₀ of GF as per published literature. DMSO when diluted in RPMI without

284 the formulations did not exhibit any inhibitory effects on *T. rubrum* NCPF 935.

285

286 **2.13. Metabolic activity of *T. rubrum* NCPF 935 by XTT assay**

287 XTT assay was used based on the method described by Costa-Orlandi *et al.*,

288 2014 with a few modifications [16]. The assay was used in this study to

289 quantify the metabolic activity of the biofilm with and without the presence of

290 the formulations. Stock solutions of XTT (2,3-bis (2-methoxy-4-nitro-5-

291 sulfophenyl)-5- [carbonyl (phenylamino)]-2H-tetrazolium hydroxide) and

292 menadione were prepared, 1 mg/mL in PBS and 1 mM ethanol respectively,

293 and stored at 4 °C. *T. rubrum* NCPF 935 biofilms were grown with and without

294 the presence of the formulations that showed the highest biofilm inhibition.

295 Samples were analysed at 3, 8, 24, 48, 72 and 96 h. To the samples, 50 µL of

296 XTT solution was added along with 4 µL of menadione into the 96-well plates

297 and incubated at 37 °C for 3 h. The resulting formation of formazan salts and

298 colorimetric change were measured in a plate reader at 490 nm (FLUOstar

299 Optima, BMG labtech, UK). RPMI 1640 medium, free of biofilm was used as a

300 negative control.

301

302 **2.14. Protease activity of *T. rubrum* NCPF 935**

303 Proteolytic activity of *T. rubrum* NCPF 935 was measured with and without the
304 presence of formulations. The method used in this study was based on Al-
305 Janabi and Al-Hamadani, 2015 with a few modifications [19]. Briefly, *T.*
306 *rubrum* NCPF 935 was grown in PDB (potato dextrose broth) (Sigma-Aldrich,
307 UK) at 37 °C in a rotary shaker at 4 RCF for 7 days. Casein from bovine milk
308 (1% w/v) (Sigma-Aldrich, UK) was used to determine the proteolytic activity.
309 Briefly, to 500 µL of the casein substrate, 500 µL of *T. rubrum* NCPF 935
310 filtrate treated with and without the formulations was added along with 100 µL
311 of 0.5 M tris-HCL (pH 8) in test tubes. The reaction was carried out at 40 °C
312 for 30 min and stopped by adding 2 mL of 0.67 M trichloro acetic acid (TCA).
313 The test tubes were allowed to rest at room temperature for 1 h. The
314 precipitate formed was removed by centrifugation at 5000 rpm for 15 min. The
315 absorbance was then measured at 280 nm using a spectrophotometer against
316 a blank where TCA was added prior to the incubation period. Unit of
317 enzymatic activity was defined as the amount of enzyme that produced
318 products by breaking down casein giving an absorbance of 0.1 at 280 nm
319 under the experimental conditions. The following formula was used to
320 calculate the activity of protease per mg of protein.

321 Protease activity (U/ mL) = OD (280 nm)/ (0.01 x Time x volume)

322

323

324

325 **2.15. Confocal laser scanning microscopy of *T. rubrum* NCPF 935**

326 **biofilm**

327 Biofilms of *T. rubrum* NCPF 935 were grown in 6-well tissue culture (Nunc)
328 plates in RPMI-1640 medium at 37 °C for a period of 72 h with and without the
329 addition of GF:HPMCAS (chloroform solvate) and non solvated (prepared
330 from acetone). FUN-1 (Molecular probes, Invitrogen) was prepared according
331 to manufactures instructions and was used to stain *T. rubrum* NCPF 935
332 biofilm as mentioned by Costa-Orlandi *et al.*, 2014 with a few modifications
333 [16]. Briefly, the biofilm was gently washed using 0.9% (v/v) saline solution
334 and treated with 300 μ L of FUN-1 fluorescent stain for 45 min and incubated at
335 37°C protected from light. After the incubation period, the excess stain was
336 gently washed using HEPES buffer after which, the biofilms were visualised at
337 ~485 nm excitation/ ~530 nm emission (green) using a Leica TSC SP2
338 confocal microscope (Heidelberg, Germany).

339

340 **2.16. Data analysis**

341 All experiments were conducted in triplicate unless mentioned otherwise.

342 Statistical analysis was conducted using one-way ANOVA (Tukey's multiple
343 comparison test). A *P* value of < 0.05 was considered to be significant. Data
344 processing was performed using GraphPad Prism 7 for windows, GraphPad
345 Software, La Jolla California, USA.

346

347

348

349

350 **3. Results**

351 **3.1. Thermal analysis of GF solid dispersions**

352 Assessment of drug/polymer interaction was based on solid solubility, which
353 was evaluated using melting point depression of corresponding physical
354 mixtures (Fig 1). As can be seen in Fig. 1, GF-HPMCAS showed lowest
355 depression of approximately 50 °C. On the contrary there was minimal
356 change in GF melting in silica and MCC dispersions signifying minimum
357 impact on the crystallinity of GF. Due to degradation of PVP, measurement of
358 GF melting in GF/PVP was not possible.

359

360 The solvated solid dispersions were also evaluated to determine any changes
361 in the melting point (Fig 1). Formation of the GF solvate was evident in the
362 DSC thermograms where an endothermic peak was clearly visible at
363 approximately 97°C (Fig. 1). This peak corresponds to the melting of
364 chloroform solvate crystals, which was confirmed via cooling cycle that
365 showed disappearance of this endotherm. The endotherm seen was
366 significant with a heat of fusion of approximately 84 J/g. Once the solvate
367 melted, another endothermic event was seen at higher temperature attributed
368 to the melt of the GF free crystals (non-solvated). The melting endotherm
369 onset of GF was 218 °C for GF prepared in chloroform (solvated), 220 and
370 219 °C for GF prepared in acetone and methanol (non-solvated), respectively.
371 The heat of fusion of crystalline GF was 86 J/g and reflected the presence of
372 the chloroform solvate because the heat of fusion for GF re-crystallized in
373 acetone and methanol was 115 J/g. This difference in heat of fusion reflects
374 a mixture of crystalline structures, i.e. crystalline GF and crystalline GF-

375 chloroform crystals. These results agreed with previous research on GF
376 solvates where the melting of the solid-chloroform solvate occurred at 147 °C
377 [20]. The lower melting peak in our results is caused by the mixing with
378 different polymers which affected the onset of the endotherm but not the
379 extent of solvation. As can be seen in Fig. 1, the chloroform solvate peaks
380 were observed in the temperature range 85-135 °C. Differences in the
381 melting onset seen among different excipients reflect variations in molecular
382 interactions where HPMCAS dispersions showed lowest onset of solvate
383 melting. Variation of the molar ratio of the solvent-GF were found previously to
384 affect the onset of the melt as was shown for different solvates [21]. This
385 possible variation was avoided via using similar ratio of the solvent throughout
386 this study.

387

388

389 **3.2. Characterization of formed dispersions by XRPD**

390 The effect of the polymer on solvate formation was studied by analysing the
391 crystalline patterns (Fig. 2). The evidence of the solvate form was confirmed
392 by the observation of the peaks at 11.3°, 15.3° and 26.5°. . It was also clear
393 that some of the peaks were less intense in the drug/polymer mixtures. This
394 could indicate presence of the partially amorphous form formation because of
395 the influence of the polymer.

396

397 The formation of the solvate was investigated further and the results can be
398 seen in Fig. 2. New peaks were seen in the scan at 2θ of 11.2°, 15.3°, 17.5°,
399 22.5°, 26.5° while other peaks such as at 10.8°, 28° and 32.8° diminished in

400 the chloroform GF solvate. These results indicate that the GF chloroform
401 solvate was formed. It was still possible to observe other peaks, which
402 indicates that the formed solvate contributed only partially to the crystalline
403 structure of GF. Changes from the chloroform solvate orthorhombic form to
404 non-solvated tetragonal (depicted from the crystalline structures) were
405 observed when temperature was increased from 30 to 200 °C and the solvate
406 disappeared completely at 120 °C. These results were similar for all drug-
407 polymer combinations. The peaks positions, and in particular at 11.2°, were
408 changing gradually and started to appear at 80 °C.

409

410

411 **Fig. 2:** (A) X-ray powder diffraction scans of 1:1 (GF : polymer) prepared in
412 acetone, chloroform and methanol and (B) X-ray powder diffraction scans of
413 1:1 (GF:HPMCAS) chloroform solvate as a function of temperature showing
414 polymorphic changes that start to occur ~90 °C. These changes result from
415 the loss of the solvate structure at this temperature range.

416

417 **3.3. Hydrogen bonding analysis of polymer-GF interactions**

418 While the formation of GF solvates was reported previously for different
419 solvents [22, 23], limited studies were carried out of solvated polymeric
420 dispersions. Fig. 3 shows the FTIR spectra obtained from 1:1 GF-polymer
421 solid dispersions in acetone, chloroform and methanol. The very broad peak
422 at 1730-1750cm⁻¹ is associated with the carbonyl group stretching of
423 HPMCAS. The peaks at 1705cm⁻¹ and 1657cm⁻¹ correspond to the stretching
424 of the benzofuran and cyclohexene carbonyl groups in GF [24]. In the
425 chloroform solid dispersion these peaks have shifted to 1694cm⁻¹ and 1666
426 cm⁻¹ respectively, indicating the presence of hydrogen bonding between
427 griseofulvin and chloroform.

428

429 The peaks at 1615cm^{-1} and 1585cm^{-1} are typically associated with the C=C
430 stretch of the aromatic ring in griseofulvin. Interestingly, in the spectrum of the
431 chloroform solid dispersion the small peak at 1599cm^{-1} which represents the
432 aromatic C=C stretch in griseofulvin disappears. Its absence indicated
433 significant polymorphic changes. The shifts were identical among different
434 polymers, which indicated predominant impact of the solvent (chloroform) in
435 the solvate formation.

436

437

438

439

440

441 **3.4. Effect of different polymers on the solubility of griseofulvin (GF)**

442 The saturation solubility of GF solid dispersions prepared in acetone,
443 chloroform and methanol are shown in Fig. 4. The solubility of GF chloroform
444 solvate was the lowest compared to that prepared from acetone or methanol
445 (35 , 45 and $70\ \mu\text{g/mL}$, respectively). However, as shown in Fig. 4,
446 incorporation of the polymers has increased the solubility of the chloroform
447 dispersion compared to GF alone. The extent of this enhancement ranged
448 from 31% for GF-MCC to 132.9% for GF-HPMCAS solid dispersions as
449 measured after 72 hours. The solubility patterns in the initial 5 hours were
450 largely similar to that of saturation solubility, with HPMCAS being the most
451 soluble and MCC being the lowest in this ascending order: MCC < silica <
452 PVP < HPMCAS.

453

454 The ability of HPMCAS to improve drug dissolution and prevent drug
455 recrystallization was also evident. HPMCAS proved to be the most effective
456 polymer to enhance solubility, with an increase up to 150%. This was
457 particularly evident in GF-HPMCAS chloroform solvate, which outperformed
458 the GF-HPMCAS in acetone solid dispersion by as much as 73%.
459 Improvements in solubility were also evident in all other polymers, with the
460 exception of silica, which solubility is almost similar to that in acetone
461 dispersions.

462

463

464

465

466

467

468

469 **3.5. Antifungal activity of solvate dispersions**

470 Formation of a biofilm is essential in the pathogenicity of *T. rubrum* to cause
471 chronic superficial fungal infections such as onychomycosis (fungal nail
472 infections). *In vitro* growth of *T. rubrum* NCPF 935 and subsequent antifungal
473 assays displayed a significant reduction in the biofilm production ($p < 0.0001$)
474 after the exposure to GF:HPMCAS chloroform solvate and non-solvated
475 GF:HPMCAS prepared from acetone when compared to the untreated
476 control.. GF chloroform solvate was found to be more effective in antagonising
477 the production of the biofilm compared to non-solvated GF prepared from

478 acetone as shown in Fig. 5 (a, b, c). As both forms of GF showed significant
479 reduction in biofilm compared to the untreated control, this in turn reflects the
480 impact of preparing the drug as a solid dispersion and the possible
481 antagonistic activity of HPMCAS towards the negating the pathogenicity of *T.*
482 *rubrum*. The antifungal activity of solvated (chloroform) and non- solvated
483 (acetone) GF against *T. rubrum* NCPF 935 is clearly observed with the XTT
484 assay wherein a significant reduction in metabolic activity was observed after
485 8h (Fig 5). This decreased metabolic activity was observed for the entire
486 duration of the experiment starting 8h at time point. Data obtained from the
487 XTT assay correspond to the reduction of the biofilm with the treatment due to
488 lowered activity of *T. rubrum* NCPF 935 and its ability to produce biofilm. As
489 shown in Fig 5, the GF chloroform solvate and non-solvated GF prepared
490 from acetone showed a significant reduction in protease activity. This reflects
491 reduced keratinolytic activity, which is important to note as one of the primary
492 virulence factors of dermatophytes.

493

494

495 Formation of hyphae is a prerequisite for fungal attachment to a substratum
496 and formation of the biofilm. Assessing the effect of GF formulations on *T.*
497 *rubrum* NCPF 935 hyphae and biofilm development by Confocal laser
498 scanning microscopy showed a change in morphology of *T. rubrum* NCPF
499 935 hyphae (density, thickness) as well as absence of conidia with treatment
500 after a period of 72 h. **Treatments therefore showed significant antagonism**
501 towards hyphal formation and subsequent propagation and spread of the

502 fungi. Similarly, absent conidia signify the reduced ability of *T. rubrum* NCPF
503 935 to sporulate, thereby negating the spread of the infection.

504

505 The chloroform solvate of GF-HPMCAS was found to have a higher impact on
506 inhibiting the biofilm development of *T. rubrum* NCPF 935. This could be
507 clearly seen in Fig 5, as thicker hyphae but not as dense were observed in
508 GF-HPMCAS dispersions (non-solvated). On the contrary, significant
509 reduction in the thickness and density as thin hyphae could be seen in the
510 GF-HPMCAS dispersions (solvated). Overall, a lack of conidia in *T. rubrum*
511 NCPF 935 was evident when treated with the GF dispersions.

512

513

514

515

516

517

518

519

520

521 **3.6. Analysis of solid and liquid state interactions using solid and liquid** 522 **state NMR**

523 Solvated GF-HPMCAS dispersion showed higher antifungal activity when
524 compared to non-solvated form. To fully understand the mechanism of this
525 enhancement, it is important to find whether the crucial interactions, which
526 were established in the liquid state, are also retained in the solid state.

527 **Nuclear magnetic resonance (NMR) is particularly suited to tackle such a**

528 problem because its offer direct inside into molecular structure in the solution
529 (liquid state NMR) and solid (solid-state NMR) and its able to provide detailed
530 information on a very subtle interactions, including hydrogen bonds.

531

532 To be able to correctly compare and analyse solution and solid-state NMR
533 results, the full assignment of all signals in ^{13}C NMR spectra of GF was
534 required (Fig. 6 and Table 1). The assignment of the signals in ^{13}C NMR
535 spectrum of GF was found to be in good agreement with previously published
536 data [25] as presented in Fig. 6A and Table 1. ^{13}C solid-state NMR spectrum
537 of pure GF showed the presence of additional signals (195 ppm and new
538 signal between 91 and 90 ppm), which could not be attributed to spinning
539 sidebands. This strongly suggests the coexistence of different isomers,
540 possibly with distinctive patterns of hydrogen bonding in the crystalline
541 dispersion as observed before [26]. This is supported by the observation that
542 resonances from the carbons C5, C2 which should be particularly sensitive to
543 hydrogen bonding are present around 195 ppm and in the region between 95
544 and 90 ppm.

545

546 The ^{13}C solid-state NMR spectra of GF, HPMCAS and GF and HPMCAS
547 dispersions are compared in Fig. 6B. There was no significant difference
548 between the spectra of physical mixture of GF and HPMCAS and a sum of the
549 separate GF and HPMCAS spectra (Fig. 6B). This suggests negligible
550 interaction in the physical mixture regardless of any conformational
551 differences in the GF isomers.

552

553

554

555

556 Fig. 6B (ii-v) compares ^{13}C solid-state NMR spectra of GF:HPMCAS
557 dispersions prepared from chloroform, acetone and methanol with the
558 spectrum of the physical mixture. For dispersions prepared from methanol, no
559 differences were observed in the chemical shifts between the physical mixture
560 and methanol dispersion indicating minimum impact of methanol on the
561 formation of the dispersion. On the other hand, the dispersion prepared using
562 acetone showed significant broadening of the signals attributed to GF with
563 mostly unchanged HPMCAS signals. For example, peaks at 97.9 and 94.5
564 ppm have merged into one broad structure at 96 ppm. These changes
565 indicate the formation of amorphous GF dispersion, which agreed with the
566 XRPD data shown above.

567

568 When comparing the chemical shifts in the spectra of the dispersion prepared
569 from chloroform, significant changes were observed especially for C14 and
570 C21 carbons (Table 1, Fig. 6A). The downfield shift in δ_{C14} ($\delta_{\text{solid}} < \delta_{\text{solution}} <$
571 δ_{complex}) suggests that stronger hydrogen bonding in the chloroform complex
572 compared to chloroform solution. In general, there were significant
573 differences in the carbon chemical shift between solution, complex –
574 dispersion and crystalline samples. This is consistent with the highly
575 constrained crystalline structure, compared with the solution where mobility of
576 the methyl groups is less restricted. Furthermore, general analysis of the

577 chemical shifts, suggests that the structure of the chloroform complex-
578 dispersion was closest to that observed in the chloroform solution (Table 1).

579

580

581

582 **4. Discussion**

583 GF was shown before to have weak activity against *T. rubrum* isolates [27].

584 However, in our work, the metabolic and protease activity of *T. rubrum* NCPF

585 935 with and without the presence of GF:HPMCAS chloroform solvates

586 showed significant reduction compared to the untreated control after 24 h

587 period. This was clearly visible in confocal laser scanning microscopy which

588 showed disappearance of the hyphae compared to Control and GF:HPMCAS

589 (non solvated). Chloroform extracts were shown before to have low activity

590 against *T. rubrum* fungal strains [28]. Therefore, results shown demonstrate

591 novel role for the polymeric dispersion in augmenting the activity of the

592 antifungal drug GF.

593

594 HPMCAS solvate dispersions were more stable when compared with other

595 polymers, which may explain the observed synergistic effect. As can be seen

596 in Figure 7, dynamic vapour sorption data showed recrystallization of all

597 solvate dispersions when the relative humidity was increased to around 70%.

598 The loss in mass was a sign of loss of bound and non-bound water (or

599 solvate). No recrystallization (or solvate loss) could be observed in HPMCAS

600 solvate dispersions upon sorption and desorption cycles which indicates that

601 the solvates maintained their structures when exposed to water.

602
603

604 Hydrogen bonding between the hydrogen in chloroform molecule and the
605 carbonyl on GF explains the basis for GF chloroform solvate formation, which
606 was clearly visible in the FTIR analysis. This ability to form hydrogen
607 bonding is based on the fact that chloroform acts as Lewis acid with the
608 potential to form hydrogen bonds with corresponding bases [29, 30]. When
609 different polymers were incorporated, the GF solvate was affected. For
610 example, HPMCAS resulted in the disruption of the solvate crystalline lattice
611 likely by formed hydrogen bonding as was shown in ^{13}C solid-state NMR
612 spectra. Polymorphic changes were confirmed using XRPD where data
613 showed despite that part of GF existed as amorphous; the main polymorphic
614 structure was the solvate form. This was clear in Fig 2 where the increase in
615 the temperature to 80°C was associated with the disappearance of the
616 solvate and appearance of form I GF polymorph. The extensive hydrogen
617 bonding for GF-HPMCAS chloroform solvate has been shown to enhance the
618 solubility of GF. This trend has also been seen for PVP where improvement
619 in solubility could also be observed when compared with the solubility of silica
620 and MCC dispersions.

621

622

623 This suggests that solvates, which were formed in the liquid state, maintained
624 their structures in the solid state. Such behaviour was reported previously
625 where lithium solvates were shown to remain stable in solutions of aprotic
626 solvents and affected the properties of those solutions [31]. Similarly, it is
627 possible that solvates formed from chloroform maintained their molecular

628 structure and assisted in enhancing solubility via Cl...Cl interactions together
629 with the formed hydrogen bonds with GF and HPMCAS. This could be
630 possible reason for the increased antifungal activity of GF-HPMCAS solvate,
631 which was 2-5 times stronger when compared with the activity of GF alone.
632 Synergistic effect was also caused by prevention of recrystallization and
633 solvate expulsion as evident in Fig. 7, which could explain the disruptive effect
634 of GF-HPMCAS on biofilms..

635

636

637

638 **5. Conclusions**

639 The results of this work showed that the griseofulvin solvate had a
640 significantly higher antifungal activity against dermatophytes compared to
641 non-solvated form. This synergistic effect was achieved by carefully planned
642 crystal engineering in which the drug properties were changed via dispersing
643 it into a matrix. Solvated crystals of griseofulvin embedded within the
644 HPMCAS matrix showed higher dissolution properties with evidence of
645 hydrogen bonding. The most significant impact of these distinctive molecular
646 interactions present in the solvate form was observed in the antimicrobial
647 assay where the fungal threads dramatically diminished when treated with the
648 chloroform solvate form of griseofulvin. Solution and solid-state NMR
649 experiments demonstrated that solvent molecules play important role in the
650 formation of very specific microstructure of the GF solid dispersions. In
651 particular, the interaction between GF and chloroform were found to be similar
652 in solution and solvate, which could be responsible for the unique properties

653 of the solvate. Our findings further signify the role of precise crystal
654 engineering in preparing highly potent versions of griseofulvin.

655

656

657

658 **Acknowledgements**

659 The authors would like to thank the Chemical Analysis Facility (CAF) at the
660 University of Reading for providing essential access to instruments used in
661 this study. We would like to thank Dr Kenneth Shankland for his help and
662 advice with the temperature controlled x-ray powder diffraction experiments.

663

664 **Declaration of Interest**

665 The authors report no conflict of interests.

666

667 **References**

668 [1] R.M. Donlan, Biofilms: Microbial life on surfaces, *Emerg Infect Dis*, 8 (2002)
669 881-890.

670 [2] K.F. Mitchell, R. Zarnowski, D.R. Andes, The Extracellular Matrix of Fungal
671 Biofilms, *Advances in experimental medicine and biology*, 931 (2016) 21-35.

672 [3] N. Hoiby, T. Bjarnsholt, C. Moser, G.L. Bassi, T. Coenye, G. Donelli, L. Hall-
673 Stoodley, V. Høla, C. Imbert, K. Kirketerp-Møller, D. Lebeaux, A. Oliver, A.J.
674 Ullmann, C. Williams, E.S.G.f. Biofilms, *Z. Consulting External Expert Werner*,
675 *ESCMID guideline for the diagnosis and treatment of biofilm infections 2014*,
676 *Clinical microbiology and infection : the official publication of the European*
677 *Society of Clinical Microbiology and Infectious Diseases*, 21 Suppl 1 (2015) S1-
678 25.

679 [4] N. Toukabri, S. Corpogno, M.E. Bougnoux, D. El Euch, N. Sadfi-Zouaoui, G.
680 Simonetti, In vitro biofilms and antifungal susceptibility of dermatophyte and
681 non-dermatophyte moulds involved in foot mycosis, *Mycoses*, 61 (2018) 79-87.

682 [5] A.K. Sahoo, R. Mahajan, Management of tinea corporis, tinea cruris, and tinea
683 pedis: A comprehensive review, *Indian dermatology online journal*, 7 (2016) 77-
684 86.

685 [6] A.B. Wingfield, A.C. Fernandez-Obregon, F.S. Wignall, D.L. Greer, Treatment of
686 tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine,
687 itraconazole and fluconazole, *The British journal of dermatology*, 150 (2004)
688 119-126.

689 [7] A.K. Gupta, J.V. Williams, M. Zaman, J. Singh, In vitro pharmacodynamic
690 characteristics of griseofulvin against dermatophyte isolates of *Trichophyton*
691 *tonsurans* from tinea capitis patients, *Medical mycology*, 47 (2009) 796-801.
692 [8] S. Stegemann, F. Leveiller, D. Franchi, H. de Jong, H. Linden, When poor
693 solubility becomes an issue: from early stage to proof of concept, *Eur J Pharm Sci*,
694 31 (2007) 249-261.
695 [9] S.S. Hate, S.M. Reutzel-Edens, L.S. Taylor, Insight into Amorphous Solid
696 Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer
697 Measurements, *Mol Pharm*, 16 (2019) 448-461.
698 [10] H.C. Arca, L.I. Mosquera-Giraldo, J.M. Pereira, N. Sriranganathan, L.S. Taylor,
699 K.J. Edgar, Rifampin Stability and Solution Concentration Enhancement Through
700 Amorphous Solid Dispersion in Cellulose omega-Carboxyalkanoate Matrices, *J*
701 *Pharm Sci*, 107 (2018) 127-138.
702 [11] A.M. Healy, Z.A. Worku, D. Kumar, A.M. Madi, Pharmaceutical solvates,
703 hydrates and amorphous forms: A special emphasis on cocrystals, *Adv Drug*
704 *Deliv Rev*, 117 (2017) 25-46.
705 [12] N. Hisada, R. Takano, N. Takata, K. Shiraki, T. Ueto, S. Tanida, M. Kataoka, S.
706 Yamashita, Characterizing the dissolution profiles of supersaturable salts,
707 cocrystals, and solvates to enhance in vivo oral absorption, *Eur J Pharm*
708 *Biopharm*, 103 (2016) 192-199.
709 [13] G. Bolla, A. Nangia, Pharmaceutical cocrystals: walking the talk, *Chemical*
710 *communications*, 52 (2016) 8342-8360.
711 [14] J. Li, K. Zhang, L. Ruan, S.F. Chin, N. Wickramasinghe, H. Liu, V. Ravikumar, J.
712 Ren, H. Duan, L. Yang, M.B. Chan-Park, Block Copolymer Nanoparticles Remove
713 Biofilms of Drug-Resistant Gram-Positive Bacteria by Nanoscale Bacterial
714 Debridement, *Nano letters*, 18 (2018) 4180-4187.
715 [15] R.S.N. Brilhante, E.E.M. Correia, G.M.M. Guedes, V.S. Pereira, J.S. Oliveira, S.P.
716 Bandeira, L.P. Alencar, A.R.C. Andrade, D. Castelo-Branco, R.A. Cordeiro, A.Q.
717 Pinheiro, L.J.Q. Chaves, W.A. Pereira Neto, J.J.C. Sidrim, M.F.G. Rocha, Quantitative
718 and structural analyses of the in vitro and ex vivo biofilm-forming ability of
719 dermatophytes, *J Med Microbiol*, 66 (2017) 1045-1052.
720 [16] C.B. Costa-Orlandi, J.C. Sardi, C.T. Santos, A.M. Fusco-Almeida, M.J. Mendes-
721 Giannini, In vitro characterization of *Trichophyton rubrum* and *T.*
722 *mentagrophytes* biofilms, *Biofouling*, 30 (2014) 719-727.
723 [17] R.M. dos Santos, M.V. Dias-Souza, Effectiveness of five antidandruff cosmetic
724 formulations against planktonic cells and biofilms of dermatophytes, *Saudi*
725 *Journal of Biological Sciences*, 24 (2017) 331-337.
726 [18] Y. Dabas, I. Xess, G. Singh, M. Pandey, S. Meena, Molecular Identification and
727 Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and
728 EUCAST Guidelines, *J Fungi (Basel)*, 3 (2017) 17.
729 [19] S.K. Kadhim, J.K. Al-Janabi, A.H. Al-Hamadani, In vitro, determination of
730 optimal conditions of growth and proteolytic activity of clinical isolates of
731 *Trichophyton rubrum*, *Journal of Contemporary Medical Sciences*, (2015) 9-
732 19%V 11.
733 [20] K. Sekiguchi, E. Suzuki, Y. Tsuda, Y. Morita, Thermal Analysis of Griseofulvin-
734 Chloroform System by High Pressure Differential Scanning Calorimetry, *Chem*
735 *Pharm Bull (Tokyo)*, 31 (1983) 2139-2141.
736 [21] S. Aitipamula, P.S. Chow, R.B. Tan, Solvates of the antifungal drug
737 griseofulvin: structural, thermochemical and conformational analysis, *Acta*

738 crystallographica Section B, Structural science, crystal engineering and materials,
739 70 (2014) 54-62.

740 [22] K.C. Cheng, E. Shefter, T. Srikrishnan, Crystal structure analysis of the
741 desolvation of the chloroform solvate of griseofulvin, International Journal of
742 Pharmaceutics, 2 (1979) 81-89.

743 [23] B.A. Bolton, P.N. Prasad, Laser Raman investigation of pharmaceutical
744 solids: griseofulvin and its solvates, J Pharm Sci, 70 (1981) 789-793.

745 [24] R. Nair, N. Nyamweya, S. Gonen, L.J. Martinez-Miranda, S.W. Hoag, Influence
746 of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a
747 thermodynamic and spectroscopic investigation, Int J Pharm, 225 (2001) 83-96.

748 [25] S.G. Levine, R.E. Hicks, H.E. Gottlieb, E. Wenkert, Carbon-13 nuclear
749 magnetic resonance spectroscopy of naturally occurring substances. XXX.
750 Griseofulvin, The Journal of organic chemistry, 40 (1975) 2540-2542.

751 [26] A. Mahieu, J.F. Willart, E. Dudognon, M.D. Eddleston, W. Jones, F. Danede, M.
752 Descamps, On the polymorphism of griseofulvin: identification of two additional
753 polymorphs, J Pharm Sci, 102 (2013) 462-468.

754 [27] D.A. Santos, J.S. Hamdan, In vitro activities of four antifungal drugs against
755 *Trichophyton rubrum* isolates exhibiting resistance to fluconazole, Mycoses, 50
756 (2007) 286-289.

757 [28] D. Rani, P.B. Khare, P.K. Dantu, In Vitro Antibacterial and Antifungal
758 Properties of Aqueous and Non-Aqueous Frond Extracts of *Psilotum nudum*,
759 *Nephrolepis biserrata* and *Nephrolepis cordifolia*, Indian journal of
760 pharmaceutical sciences, 72 (2010) 818-822.

761 [29] A.V. Lesikar, Effect of association complexes on the glass transition in
762 organic halide mixtures, The Journal of Physical Chemistry, 80 (1976) 1005-
763 1011.

764 [30] F. Ito, Matrix-isolation infrared studies of 1:1 molecular complexes
765 containing chloroform (CHCl₃) and Lewis bases: seamless transition from blue-
766 shifted to red-shifted hydrogen bonds, J Chem Phys, 137 (2012) 014505.

767 [31] D. Brouillette, D.E. Irish, N.J. Taylor, G. Perron, M. Odziemkowski, J.E.
768 Desnoyers, Stable solvates in solution of lithium
769 bis(trifluoromethylsulfone)imide in glymes and other aprotic solvents: Phase
770 diagrams, crystallography and Raman spectroscopy, Physical Chemistry
771 Chemical Physics, 4 (2002) 6063-6071.

772
773
774
775
776
777
778
779
780
781
782
783
784
785
786

787 **Legend to Tables and Figures**

788

789 **Supplementary Table 1:** Typical *in vitro* concentrations of GF:HPMCAS used
790 in relation to MIC₉₀ of GF

791

792 **Table 1:** A summary of NMR chemical shifts as measured for GF:HPMCAS
793 (1:1) using ¹³C CPMAS and ¹³C liquid NMR and their assignment to the
794 molecular structure of GF (see Fig. 6A for full numbering of carbon atoms).

795

796 **Fig. 1:** Thermograms of GF mixtures with polymers (A) showing the melting
797 point of GF in physical mixtures with the polymers, and (B) showing
798 thermograms of solid dispersions prepared in chloroform, methanol, acetone
799 using a weight ratio of 1:1. The chloroform solvate peaks can be seen in the
800 temperature range 85-135 °C.

801

802 **Fig. 2:** (A) X-ray powder diffraction scans of 1:1 (GF : polymer) prepared in
803 acetone, chloroform and methanol and (B) X-ray powder diffraction scans of
804 1:1 (GF:HPMCAS) chloroform solvate as a function of temperature showing
805 polymorphic changes that start to occur ~90 °C. These changes result from
806 the loss of the solvate structure at this temperature range.

807

808 **Fig. 3:** FTIR scans of 1:1 (GF : polymer) prepared in acetone, chloroform and
809 methanol showing significant changes in the chloroform solvates as reflected
810 in the stretching vibrations highlighted by the shaded bars.

811

812 **Fig. 4:** saturated solubility measurements showing solubility of pure GF
813 crystallized from different solvents and GF : polymer (1:1) prepared using
814 different solvents. Measurements were performed in a phosphate buffer
815 (pH=6.8), t=72 hours , n=3.

816

817 **Fig. 5:** (A) Quantification of biofilm formed by *T. rubrum* NCPF 935 by
818 safranin staining. Compared to the control, the use solvated and non solvated
819 GF:HPMCAS dispersions showed a significant reduction in biofilm content ($p <$
820 0.0001), (B) Metabolic activity of *T. rubrum* NCPF 935 with and without the
821 presence of formulations GF:HPMCAS (chloroform solvate) and GF:HPMCAS
822 non solvated (prepared from acetone) showed a significant reduction
823 compared to the untreated control after 24 h period 96 h (n=3), (C)
824 Quantification of protease activity by *T. rubrum* NCPF 935 showing significant
825 reduction ($p < 0.0001$) in protease activity (n=5) and (D) confocal laser
826 scanning microscopy images of *T. rubrum* NCPF 935 with and without
827 treatment after 72 h (magnification at 630x). i) Control *T. rubrum* growth
828 shows conidia (white arrows) and dense hyphae. ii) Treatment with
829 GF:HPMCAS non solvated (prepared from acetone) showed thicker hyphae
830 but not as dense. iii) Treatment with GF:HPMCAS (chloroform solvate)
831 showed thin hyphae compared to Control and GF:HPMCAS non solvated
832 (prepared from acetone).

833

834 **Fig. 6:** (A) Molecular structure of GF and the assignment of the carbon atoms
835 to the resonances recorded in (ii) solid-state and (i) solution ¹³C NMR spectra.
836 (B) Comparison of ¹³C solid-state NMR spectra of (i) GF and HPMCAS, (ii)

837 physical mixture of GF and HPMCAS, and GF:HPMCAS dispersions prepared
838 from (iii) chloroform, (iv) acetone and (v) methanol.

839

840 ***Fig. 7: Dynamic vapour sorption isotherms for GF solid dispersions prepared***
841 ***using chloroform.***

842

843

844

845

846

847

848